Premium
IL‐6 supplementation increases thermotolerance and reduces intestinal permeability in anesthetized mice
Author(s) -
Clanton Thomas L,
Phillips Neil A,
Novosad Veronica L,
OcaCossio Jose,
Welc Steven S
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.1052.2
Subject(s) - hyperthermia , heatstroke , core temperature , endocrinology , chemistry , ratón , medicine
The role of IL‐6 in hyperthermia is poorly understood. However, plasma IL‐6 is elevated following heatstroke in animals and humans, and IL‐6 knockout mice have been shown to be intolerant of hyperthermia (Leon, 2006, Prog Brain Res). We tested the effect of IL‐6 supplementation on the progression of heatstroke in anesthetized mice. Mice were exposed to incremental, 0.5°C/30 min increases in environmental temperature, starting from 39.5°C, until a core temperature reached 42.5°C. Mice that survived the protocol were then returned to 22°C environmental temperature for 30 min. Control mice (N= 16) were tested vs. mice pre‐treated with 0.6 μg IL‐6 (IP) (N=11), or combined 0.6 μg IL‐6 (IP)+ 0.6 μg sIL‐6r (soluble IL‐6 receptor)(N=4). The survival time was longer for IL‐6 and IL‐6+sIL‐6r groups compared to controls (P < 0.01; survival analysis). The time tolerated was 82 ± 6 vs. 122 ± 12 SE min in controls vs. IL‐6 treated mice (P = 0.01). Prior to anesthesia, mice were gavaged with 250 μL 4kDa FITC‐dextran (FD). At sacrifice, plasma FD was higher in hyperthermia mice (N=16) compared to unheated, time‐matched controls (N=9) (P<0.02), whereas hyperthermia mice pre‐treated with IL‐6 (N = 8), were not different from controls. The results are consistent with IL‐6 playing a protective role during hyperthermia, in part through reductions in heat‐induced intestinal permeability (NHLB 53333).